Advertisement
Home Tags Herpes Zoster (Shingles)

Tag: Herpes Zoster (Shingles)

The risk for herpes zoster is elevated during the two years preceding diagnosis and during treatment of hematological cancer

Risk for Zoster Up Before Dx, During Tx of Hematologic Cancer

0
For solid organ cancers, the risk is greater among those receiving chemotherapy
The herpes zoster adjuvant recombinant subunit vaccine may be more effective than the live attenuated vaccine

Herpes Zoster Recombinant Vaccine Seems Most Effective

0
However, adjuvant recombinant subunit vaccine tied to more injection site adverse events
Recipients of the herpes zoster subunit vaccine

Robust Immune Responses for Herpes Zoster Subunit Vaccine

0
Humoral response seen for 97.8 percent of HZ/su vaccine recipients versus 2 percent of placebo
The new adjuvanted herpes zoster subunit vaccine is cost-effective compared with the currently recommended live attenuated herpes zoster vaccine

Adjuvanted Shingles Subunit Vaccine Likely More Cost-Effective

0
Less overall cost and more effective than live attenuated vaccine at all ages; generally a good value
Herpes zoster may be associated with an increased risk of cardiovascular events

Herpes Zoster May Increase Risk of Myocardial Infarction, Stroke

0
More research is needed, but doctors should warn patients, researcher says
From 2006 to 2013 there was an increase in the number of emergency department visits for herpes zoster

2006 to 2013 Saw Increase in ER Use for Herpes Zoster

0
Increase in number of emergency department visits and costs for HZ-related ER visits
For patients with autoimmune diseases

Zoster Ups Stroke Risk in Patients With Autoimmune Disease

0
For patients with autoimmune disease, herpes zoster tied to increased stroke risk in first 90 days
Among adults with diagnosed diabetes

CDC Finds Vaccination Coverage Varies for Adults With Diabetes

0
Influenza vaccination coverage more prevalent than pneumococcal or hepatitis B vaccination
An experimental vaccine against herpes zoster may offer lasting protection for most older adults who receive it

Experimental Zoster Vaccine Effective in Adults Aged 70+

0
Found to protect 89.8 percent of adults age 70 and up
For patients with herpes zoster

Pain and Itch Highly Prevalent Months After Herpes Zoster

0
Pain linked to increased costs and has large impact on quality of life; itch has limited impact on QoL